Thorsten Ruf

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

Tony Mok, D. Ross Camidge, Shirish M. Gadgeel et al. · Annals of Oncology · 2020 · 656 citations · Full text

Alectinib in Resected <i>ALK</i> -Positive Non–Small-Cell Lung Cancer

Yi‐Long Wu, Rafał Dziadziuszko, Jin Seok Ahn et al. · New England Journal of Medicine · 2024 · 320 citations

Existence of the Frank-Starling Mechanism in the Failing Human Heart

Christian Holubarsch, Thorsten Ruf, Daniel J. Goldstein et al. · Circulation · 1996 · 237 citations

LBA2 ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC)

Benjamin Solomon, Jin Seok Ahn, Rafał Dziadziuszko et al. · Annals of Oncology · 2023 · 71 citations

Oncology, Pharmacology, Immune Checkpoint Inhibitor +4

Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer

Jennifer Moriatis Wolf, Åslaug Helland, In‐Jae Oh et al. · ESMO Open · 2022 · 48 citations · Full text